CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026

CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics for genetic diseases, on Friday reported financial results for the second quarter ended June 30, 2026, and provided corporate updates.